1. Pink Sheet
  2. >>Geography
  3. >>Europe

Price-Based Procurement Could Be Pushing Down Vaccination Coverage

More Flexibility Needed In Purchasing Mechanisms

 
• By Francesca Bruce

A new study argues that certain procurement methods could be hitting vaccine coverage rates and that wider debate is needed among policy makers, payers and procurers to find more sophisticated purchasing models.

Medical concept Vaccination vaccine vial dose flu shot drug needle syringe,Lab test research science hypodermic injection treatment disease care hospital prevention immunization illness disease baby.
Procurement Of Vaccines Should Not Focus Solely On Price • Source: Shutterstock

Procurement models like price-based tendering could be to blame for a decline in vaccine coverage rates, argues an analysis published in the peer-reviewed journal Expert Review of Vaccines. Models that allow more flexibility and focus on factors beyond price, such as value-added services that counter anti-vaccination campaigns, can help contribute to a sustainable “vaccine ecosystem,” it says.

“There is certainly a correlation between the use of some forms of tendering and procurement and reduction in the level of coverage,” according to Tim Wilsdon, vice president in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 
• By Eliza Slawther

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.

More from Geography

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.